Form 4 for ABBV AbbVie
Accepted 2024-02-20 00:00:00 ET · period of report 2024-02-15 · accession 0001415889-24-004416 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-20 | 2024-02-15 | ABBV | Michael Robert A. | Pres, COO | A - Grant | $0.00 | +85.0K | 183.6K | +86% | $0 |
| D | 2024-02-20 | 2024-02-15 | ABBV | Michael Robert A. | Pres, COO | A - Grant | $0.00 | +59.9K | 59.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 par value | 2024-02-15 | A | A | 49,565 | $0.00 | 148,210 | D | — | — | (F1) Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| 2 | Common | Common Stock, $0.01 par value | 2024-02-15 | A | A | 13,216 | $0.00 | 161,426 | D | — | — | (F2) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| 3 | Common | Common Stock, $0.01 par value | 2024-02-15 | A | A | 10,146 | $0.00 | 171,572 | D | — | — | (F3) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| 4 | Common | Common Stock, $0.01 par value | 2024-02-15 | A | A | 12,030 | $0.00 | 183,602 | D | — | — | (F4) Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. |
| 5 | Derivative | Option (Right to Buy) | 2024-02-15 | A | A | 59,888 | $0.00 | 59,888 | D | $0.00 · 2025-02-15 to 2034-02-14 | 59,888 Common Stock | (F5) Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,963 on February 15, 2025, 19,963 on February 15, 2026, and 19,962 on February 15, 2027. |